Amarantus Bioscience Holdings Inc - ESG Rating & Company Profile powered by AI
This report of Amarantus Bioscience Holdings Inc leverages information from across the web as well as from public disclosures by Amarantus Bioscience Holdings Inc. Comprehensive ESG analysis of Amarantus Bioscience Holdings Inc can be reached by signing up for free. Alternative companies in the scoring industry group for Amarantus Bioscience Holdings Inc are displayed below.
Amarantus Bioscience Holdings Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1967 | Hospira Inc | 0.3 | Low |
1967 | PRA Health Sciences Inc | 0.3 | Low |
1970 | Amarantus Bioscience Holdings Inc | 0.0 | Low |
1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
1970 | CTC Bio Inc | 0.0 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Amarantus Bioscience Holdings Inc have an accelerator or VC vehicle to help deliver innovation?
Does Amarantus Bioscience Holdings Inc disclose current and historical energy intensity?
Does Amarantus Bioscience Holdings Inc report the average age of the workforce?
Does Amarantus Bioscience Holdings Inc reference operational or capital allocation in relation to climate change?
Does Amarantus Bioscience Holdings Inc disclose its ethnicity pay gap?
Does Amarantus Bioscience Holdings Inc disclose cybersecurity risks?
Does Amarantus Bioscience Holdings Inc offer flexible work?
Does Amarantus Bioscience Holdings Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Amarantus Bioscience Holdings Inc disclose the number of employees in R&D functions?
Does Amarantus Bioscience Holdings Inc conduct supply chain audits?
Does Amarantus Bioscience Holdings Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Amarantus Bioscience Holdings Inc conduct 360 degree staff reviews?
Does Amarantus Bioscience Holdings Inc disclose the individual responsible for D&I?
Does Amarantus Bioscience Holdings Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Amarantus Bioscience Holdings Inc disclose current and / or historical scope 2 emissions?
Does Amarantus Bioscience Holdings Inc disclose water use targets?
Does Amarantus Bioscience Holdings Inc have careers partnerships with academic institutions?
Did Amarantus Bioscience Holdings Inc have a product recall in the last two years?
Does Amarantus Bioscience Holdings Inc disclose incidents of discrimination?
Does Amarantus Bioscience Holdings Inc allow for Work Councils/Collective Agreements to be formed?
Has Amarantus Bioscience Holdings Inc issued a profit warning in the past 24 months?
Does Amarantus Bioscience Holdings Inc disclose parental leave metrics?
Does Amarantus Bioscience Holdings Inc disclose climate scenario or pathway analysis?
Does Amarantus Bioscience Holdings Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Amarantus Bioscience Holdings Inc disclose the pay ratio of women to men?
Does Amarantus Bioscience Holdings Inc support suppliers with sustainability related research and development?
Does Amarantus Bioscience Holdings Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Amarantus Bioscience Holdings Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Amarantus Bioscience Holdings Inc involved in embryonic stem cell research?
Does Amarantus Bioscience Holdings Inc disclose GHG and Air Emissions intensity?
Does Amarantus Bioscience Holdings Inc disclose its waste policy?
Does Amarantus Bioscience Holdings Inc report according to TCFD requirements?
Does Amarantus Bioscience Holdings Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Amarantus Bioscience Holdings Inc disclose energy use targets?
Does Amarantus Bioscience Holdings Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Amarantus Bioscience Holdings Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Amarantus Bioscience Holdings Inc
These potential risks are based on the size, segment and geographies of the company.
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.